Shilpa Medicare Receives NCLT Approval for Subsidiary Merger to Streamline Operations
核心洞察
Shilpa Medicare Limited received National Company Law Tribunal (搜索) approval on February 27, 2026, for amalgamation with wholly owned subsidiary Shilpa Therapeutics Private Limited (搜索) under the Companies Act 2013.
The merger will transfer all assets, liabilities, and undertakings from the subsidiary to the parent company, with no new shares issued due to complete ownership structure.
All employees of Shilpa Therapeutics will be absorbed by Shilpa Medicare on terms no less favorable than current arrangements, ensuring job protection during the transition.
Shilpa Medicare Limited has secured approval from the National Company Law Tribunal (搜索) (NCLT) Bengaluru Bench for its scheme of amalgamation with wholly owned subsidiary Shilpa Therapeutics Private Limited (搜索). The tribunal issued its order on February 27, 2026, under sections 230-232 of the Companies Act, 2013, with the appointed date set as April 1, 2025.
Merger Structure and Financial Impact
The amalgamation involves the complete absorption of Shilpa Therapeutics into its parent company. Shilpa Therapeutics reported revenue from operations of ₹2.32 crores and ₹3.07 crores for financial years ending March 31, 2023, and March 31, 2024, respectively. The subsidiary showed employee benefit expenses of ₹1.39 crores as of March 31, 2024.
Under the approved scheme, no new shares will be issued by Shilpa Medicare since Shilpa Therapeutics is a wholly owned subsidiary. All existing shares of the subsidiary held by Shilpa Medicare and its nominees will be cancelled upon the scheme's effectiveness. The authorized share capital of both companies will be combined as part of the merger process.
Employee Protection and Operational Integration
The merger ensures comprehensive protection of employee interests. All staff, workmen, and employees of Shilpa Therapeutics will become employees of Shilpa Medicare on terms not less favorable than their current conditions, without any break in service. This provision addresses the subsidiary's workforce while maintaining continuity of operations.
Regulatory Compliance Requirements
The NCLT order includes several compliance obligations that Shilpa Medicare must fulfill:
Outstanding Dues Management:
- Transferor company MSME dues: ₹25.60 lakhs
- Transferee company MSME dues: ₹53.13 lakhs
- Transferor company statutory dues: ₹61.17 lakhs
- Transferee company statutory dues: ₹3.59 crores
The company has provided comprehensive undertakings to various statutory authorities, including FEMA compliance for foreign exchange regulations, commitment to settle dues to Micro, Small and Medium Enterprises, and compliance with Income Tax Act provisions. The tribunal has directed the company to comply with Section 170A of the Income Tax Act, 1961 within the prescribed period.
Capital Structure Details
Shilpa Therapeutics Private Limited (搜索) has an authorized share capital of ₹3.00 crores, comprising equity share capital of ₹2.00 crores and preference share capital of ₹1.00 crore. The issued, subscribed and paid-up capital stands at ₹1.84 crores divided into equity shares and preference shares.
Shilpa Medicare Limited's authorized share capital has been increased to ₹56.00 crores following previous merger approvals. The company's shares are listed on both NSE and BSE.
Implementation Timeline
The scheme will become effective once certified copies of the NCLT order are filed with the Registrar of Companies and other conditions specified in the scheme are fulfilled. Shilpa Medicare received the certified copy of the tribunal order on March 16, 2026, and must complete the filing process to activate the merger.
The merger is expected to streamline operations and enhance operational efficiency for the combined entity by consolidating resources and eliminating subsidiary management overhead.